BIOMAT Database Logo BIOMAT Database Logo

Successful treatment of antimony-resistant cutaneous leishmaniasis with liposomal amphotericin B. 1994

J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó

UI MeSH Term Description Entries
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000965 Antimony A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.
D016773 Leishmaniasis, Cutaneous An endemic disease that is characterized by the development of single or multiple localized lesions on exposed areas of skin that typically ulcerate. The disease has been divided into Old and New World forms. Old World leishmaniasis is separated into three distinct types according to epidemiology and clinical manifestations and is caused by species of the L. tropica and L. aethiopica complexes as well as by species of the L. major genus. New World leishmaniasis, also called American leishmaniasis, occurs in South and Central America and is caused by species of the L. mexicana or L. braziliensis complexes. Leishmaniasis, American,Leishmaniasis, New World,Leishmaniasis, Old World,Oriental Sore,American Leishmaniasis,Cutaneous Leishmaniases,Cutaneous Leishmaniasis,Leishmaniases, Cutaneous,New World Leishmaniasis,Old World Leishmaniasis,Sore, Oriental

Related Publications

J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Successful treatment of resistant visceral leishmaniasis with liposomal amphotericin B.
January 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene,
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
July 2005, The British journal of dermatology,
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B (L-AmpB-LRC) in a child.
April 1995, Tropical doctor,
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
October 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
[Treatment of cutaneous leishmaniasis with liposomal amphotericin B].
August 2010, Anales de pediatria (Barcelona, Spain : 2003),
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
[Successful treatment of antimony-resistant cutaneous leishmaniasis].
December 1987, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Two cases of successful treatment of multilesional cutaneous leishmaniasis with liposomal amphotericin B.
January 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG,
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Successful treatment of visceral leishmaniasis with liposomal amphotericin B.
January 2006, Acta bio-medica : Atenei Parmensis,
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B.
September 2021, Pathogens (Basel, Switzerland),
J Torre-Cisneros, and J L Prada, and J L Villanueva, and F Valverde, and P Sánchez-Guijó
Treatment of pediatric cutaneous leishmaniasis with liposomal amphotericin B.
September 2022, Dermatologic therapy,
Copied contents to your clipboard!